Flagship christens the latest startup to join the drug discovery fleet, this time focused on the lessons of cell death
A few years ago, Flagship managing partner Doug Cole began to pick at the notion that cell death could offer a rich source of information on new drugs. After all, intercellular communication between living cells had long been mined for insights into the role of neurotransmitters and cytokines and so forth that made up the central focus for numerous startups.
He put together a team, with Jason Park, that began to assemble what was known about cell death, and also started doing their own experiments with mice to see what they could add as they tracked what happened when they triggered different kinds of cell death.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.